506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Stopped early · Phase 1

Conditions studied: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer and kidney or liver impairment.

Key facts

Study ID

NCT00004239

Run by

Alliance for Clinical Trials in Oncology

People needed

10

Starts

1999-12-01

Expected to finish

2002-01-01

Last updated by the study team

2016-07-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Holden Comprehensive Cancer Center at The University of Iowa — Iowa City, Iowa, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.